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Abstract Mutations in the hepatocyte nuclear factor 4K (HNF-
4K) gene are associated with one form of maturity-onset diabetes
of the young (MODY1). The R154X mutation generates a
protein lacking the E-domain which is required for normal HNF-
4K functions. Since pancreatic L-cell dysfunction is a feature of
MODY1 patients, we compared the functional properties of the
R154X mutant in insulin-secreting pancreatic L-cells and non-L-
cells. The R154X mutation did not affect nuclear localisation in
L-cells and non-L-cells. However, it did lead to a greater
impairment of HNF-4K function in L-cells compared to non-L-
cells, including a complete loss of transactivation activity and a
dominant-negative behaviour. ß 2000 Federation of European
Biochemical Societies. Published by Elsevier Science B.V. All
rights reserved.
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1. Introduction
Mutations in the hepatocyte nuclear factor-4K (HNF-4K)
are the cause of the type 1 form of maturity-onset diabetes
of the young (MODY) (OMIM 125850) which is a monogenic
form of diabetes characterised by an early age at onset (usu-
ally before 25 years), autosomal dominant inheritance and
abnormal pancreatic L-cell function [1]. HNF-4K regulates
normal pancreatic L-cell function and controls expression of
genes involved in glucose transport and metabolism [2]. It also
regulates the expression of transcription factors such as HNF-
1K [3^5].
Like other members of the hormone nuclear receptor super-
family, HNF-4K has a modular structure consisting of func-
tional domains named A^F (Fig. 1A). HNF-4K contains two
transactivation function modules AF-1 and AF-2 located at
the amino-terminal end of domain A and the carboxy-termi-
nal end of domain E, respectively [6,7]. Domain E is involved
in dimerisation [8] and interactions with other transcription
factors [9,10] and coactivators [11^14].
Studies of functional properties of several diabetes-associ-
ated mutations of HNF-4K have shown that mutations can
have variable e¡ects on the ability of HNF-4K to transactivate
a reporter gene [2,15^18]. The R154X mutation generates a
protein that has an intact DNA binding domain but lacks the
E-domain [19]. Lausen et al. have recently described some of
the properties of R154X in non-pancreatic L-cells [16]. The
results presented here extend their studies and describe func-
tional properties of the mutant protein that may explain how
this mutation leads to abnormal HNF-4K function in pancre-
atic L-cells and could contribute to the development of the
MODY1 form of diabetes.
2. Materials and methods
2.1. DNA Constructs
The wild-type and R154X human HNF-4K2 were cloned in
pcDNA3.1/HisB (Invitrogen). The p enhanced green £uorescent pro-
tein (EGFP)-HNF-4K2 and pEGFP-R154X were cloned in pEGFP-
C1 (Clontech). The HNF-4K 1^358 construct was obtained by a meth-
od similar to that used to prepare the HNF-4vF [20] with the oligo-
nucleotide 5P-CGTTCTAGATTAGTCAATCTTGGCCATGC-3P as
the antisense primer. The HNF-1K, apolipoprotein CIII (apoCIII),
-186 liver pyruvate kinase (LPK) and (L4L3)3x-96 LPK promoter^
reporter constructs have been described previously [18,21]. The
(PEPCK)4xTATA box construct which includes four copies of the
HNF-4 response element in the rat PEPCK promoter (nucleotides
3456 to 3436) cloned upstream of the TATA box of the adenovirus
major late promoter and luciferase reporter gene was prepared as
described in [20]. The sequences of all constructs were veri¢ed by
DNA sequencing.
2.2. Cell culture and transient transfection assays
COS-1 and HEK 293T cells (2U105 cells and 5U105 cells per 6 well
dish, respectively) were grown as in [18]. HIT-T15 cells (ATCC CRL-
1777) (5U105 cells per 6 well dish and passages 69^80) were grown in
RPMI 1640 medium containing 4 mM glucose and supplemented with
10% FCS, 10 mM HEPES pH 7.4, 100 U/ml penicillin and 100Wg/ml
streptomycin. Transfections and luciferase assays were carried out as
described previously [18].
2.3. Subcellular localisation of HNF-4K
Transfection of cells and confocal laser scanning microscopy were
carried out as indicated in [22] using an oil Pl Apo 100U (NA = 1.4)
objective.
2.4. Western blot assays
Western blot assays were carried out as in [17] using either the
K-455 antiserum raised against the carboxy-terminal sequence of
HNF-4K [23] or the anti-Xpress antibody (Invitrogen) which rec-
ognises the Xpress-epitope tag of proteins expressed from the
pcDNA3.1/HisB.
2.5. Electrophoretic mobility shift assays (EMSA)
EMSA were performed as in [20]. Proteins were in vitro synthesised
as indicated in [18].
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3. Results
3.1. R154X mutant is localised in the nucleus
Nuclear translocation of nuclear receptors involves motifs
termed nuclear localisation signals (NLSs). The NLS1 which
is localised at the C/D-domain junction, displays a constitu-
tive nuclear targeting activity. However, complete nuclear
translocation requires the cooperation with another NLS lo-
cated in the ligand binding domain E (for review see [24]). The
C/D-domain junction of HNF-4K contains a sequence with 10
basic residues that is strictly conserved between HNF-4K and
HNF-4Q and is similar to clusters of basic residues that con-
stitute the NLS1 of other nuclear receptors (Fig. 1B). The
R154X has the C/D-domain element but lacks the E-domain
element (Fig. 1A). Our ¢rst goal was to investigate the sub-
cellular localisation of R154X.
Fig. 1. R154X mutant is localised in the nucleus. A: Schematic rep-
resentation of HNF-4K2 and R154X mutant. Numbers indicate ami-
no acid positions at the amino- and carboxy-terminus of these pro-
teins; functional domains A^F are shown at the top; diamonds and
hexagons depict activation function modules AF-1 and AF-2, re-
spectively. The star depicts the last cysteine residue of the DNA
binding domain (DBD) localised in domain C. B: The NLSs in the
C/D-domain junction of nuclear receptors. The last cysteine residue
in the DBD is indicated by a star. Basic residues are in bold. The
box corresponds to a basic motif that is conserved in the steroid re-
ceptor subfamily [24]. Numbers on the left indicate the positions in
the amino acid sequences. C: Subcellular distribution of EGFP-
HNF-4K2 and EGFP-R154X in HIT-T15 (a and b, respectively)
and in HeLa cells (c and d, respectively). The £uorescence images
were observed by confocal laser scanning microscopy. Bars indicate
5 Wm. D: HNF-4K expression in HIT-T15 cells. Western blot of
HIT-T15 whole cell extracts (5 Wg) revealed with the K-455 antise-
rum. Numbers indicate the molecular mass of protein markers in
kDa.
Fig. 2. Transactivation activities of R154X mutant. A, B and C: ac-
tivities in COS-1, HIT-T15 and HEK 293T cells, respectively. apoC-
III, apoCIII promoter; HNF-1K, HNF-1K promoter; -183 LPK,
LPK promoter; (L4L3)3x-96 LPK, three tandem repeats of the adja-
cent glucose and HNF-4K response elements upstream of the LPK
promoter; (PEPCK)4x-TATA, four copies of the HNF-4K response
element from the PEPCK gene upstream of the TATA box. These
promoters (1 Wg) were cotransfected with 50 ng of HNF-4K expres-
sion vectors. White, black and grey columns represent the activities
obtained in the absence or in the presence of wild-type and R154X
HNF-4K, respectively. Fold induction refers to the activity with no
HNF-4K derivative. Data are means þ S.D. for at least three experi-
ments. D: Western blotting. Nuclear proteins were resolved by
SDS^PAGE and transferred on a PDVF membrane. The HNF-4K
proteins were detected using the anti-Xpress antibody. Numbers in-
dicate the molecular mass of protein markers in kDa.
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EGFP-HNF-4K2 and EGFP-R154X that have the EGFP
fused in frame to HNF-4K2 and R154X, respectively, were
expressed in HIT-T15 pancreatic L-cells. Both proteins were
exclusively localised in the nucleus of cells expressing these
proteins and no green £uorescence was detected in the cyto-
plasm (Fig. 1C, a and b). As previously reported, EGFP alone
is uniformly distributed in the cell and has to be fused to a
protein that translocates to the nucleus to accumulate in this
cell compartment [22,25]. Since HIT-T15 cells express endog-
enous HNF-4K, as determined by Western blot (Fig. 1D), the
nuclear accumulation of EGFP-R154X may result from its
passive transport as a heterodimer formed with the wild-
type HNF-4K [26]. Therefore, the nuclear localisation studies
were carried out using HeLa cells which do not express HNF-
4K and again, the expression of both £uorescent proteins was
restricted to the nucleus (Fig. 1C, c and d).
3.2. Transactivation activity of R154X
In the COS-1 kidney cell line, R154X failed to transactivate
(L4L3)3x-96 LPK and (PEPCK)4x TATA promoters which
contain tandem repeats of the HNF-4K response elements of
the LPK and PEPCK genes (Fig. 2A). However, it was able to
moderately activate the HNF-1K and apoCIII promoters
(50% when compared to HNF4-K2). A moderate transactiva-
tion activity of R154X on the HNF-1K promoter was also
observed in the other kidney cell line HEK 293T (Fig. 2C).
The di¡erences in transactivation activities between HNF-4K
and R154X were not due to di¡erences in their expression as
determined by Western blotting (Fig. 2D). By contrast,
R154X could not transactivate any of the tested promoters
in HIT-T15 cells (Fig. 2B). Similar transactivation activities
were observed using HNF-4K2 and R154X lacking the
Xpress-epitope tag (data not shown), ascertaining that this
tag does not modulate the transcriptional activity of HNF-4K.
3.3. E¡ects of R154X HNF-4K on the activities of the wild-type
HNF-4K2
MODY1 patients express both wild-type and mutant forms
of HNF-4K. It is therefore of interest to determine whether
the reduced expression of HNF-4K target genes is due to
haploinsu⁄ciency or to an impaired activity of the wild-type
HNF-4K by a dominant negative activity of the mutant, thus
decreasing the available amount of e⁄cient HNF-4K. This is
particularly important in pancreatic L-cells where normal
HNF-4K expression is lower than in liver or kidney [27].
This led us to investigate whether R154X could alter the
transactivation activity of the wild-type protein. In COS-1
cells, the activity of HNF-4K2 on the (L4L3)3x-96 LPK pro-
moter was not a¡ected by the presence of an equal amount of
R154X but larger amounts caused a slight reduction in activ-
ity (Fig. 3A). A much stronger repression of the wild-type
HNF-4K2 transactivation activity was observed upon addition
of HNF-4K(1^358), an HNF-4K mutant lacking the AF-2
module and having a strong dominant negative activity [6]
(Fig. 3A). Interestingly, a stronger dominant-negative e¡ect
of R154X was observed in HIT-T15 cells (Fig. 3B).
These results led us to analyse, by EMSA, the e¡ect of
R154X on the binding activity of HNF-4K2 on the HNF-4K
response element of the LPK gene (LPK L3) [21]. The band-
Fig. 3. E¡ects of R154X on the transactivation activity of HNF-
4K2. COS-1 cells (A) and HIT-T15 cells (B) were transfected with
constant amounts of (L4L3)3x-96LPK reporter (1 Wg) and HNF-4K2
expression vector (50 ng) together with indicated amounts of vectors
expressing either R154X mutant (squares) or HNF-4(1^358) (trian-
gles). In every case vector DNA (pcDNA3.1His) was added as nec-
essary to achieve a constant amount of transfected DNA. Results
are expressed as percentage of the activity of the promoter when ac-
tivated by HNF-4K2 alone. Data are means þ S.D. of three experi-
ments performed in quadruplicate.
Fig. 4. E¡ects of R154X on the DNA-binding activity of HNF-4K2.
32P-labelled LPK L3 was incubated with in vitro synthesised HNF-
4K2 (WT), R154X and HNF-1K P291fsinsC (HNF-1 m) using the
fold molar amounts of R154X and HNF-1K P291fsinsC over HNF-
4K2 indicated in A. B: Supershift of the HNF-4K2-LPK L3 com-
plex yielded by incubation with 0.1 Wl of K-455 antiserum contain-
ing the antibodies raised against the carboxy-terminal sequence of
the protein (ab). Control of protein synthesis performed in the pres-
ence of [35S]methionine is presented in panel C where numbers on
the left indicate the molecular mass of the markers in kDa. 1Wl of
protein synthesis was loaded except 2 Wl of HNF-1K P291fsinsC due
to its low content in methionine residues (4 versus 19 in Xpress-tag-
HNF-4K2).
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shift yielded by wild-type HNF-4K2 (Fig. 4A, lane 1) was
speci¢c since it was supershifted by the K-455 antibody raised
against HNF-4K (Fig. 4B). When identical molar amounts of
HNF-4K2 and R154X were incubated with the LPK L3
probe, we observed a 20% decrease in the DNA binding ac-
tivity of HNF-4K2 (Fig. 4A, lane 2). The DNA binding inhi-
bition was clearly concentration-dependent (Fig. 4A, lanes 3
and 4). Both wild-type and R154X proteins were e⁄ciently
expressed (Fig. 4C). This decrease was speci¢cally due to
R154X since it was not observed upon addition of the unre-
lated protein human HNF-1K P291fsinsC (Fig. 4A, lanes 5^7).
This truncated HNF-1K lacks the domain located between
residues 280 and 440 which is required for HNF-1K^HNF-
4K interaction [10]. HNF-1K P291fsinsC which yielded a band
at its expected molecular size (37 kDa) in SDS^PAGE (Fig.
4C) could not bind the LPK L3 probe (Fig. 4A, lane 8).
4. Discussion
Our results showing that the R154X HNF-4K mutant was
e⁄ciently translocated to the nucleus indicate that the E-do-
main of HNF-4K is not required for e⁄cient nuclear target-
ing.
R154X exhibited strong impairment in transactivation ac-
tivity, the extent of which varied with target promoters. In
COS-1 cells, the transactivation activity of R154X was com-
pletely lost on two promoters and remained moderate (50% of
that induced by wild-type HNF-4K2) on two other promoters
tested. It has been previously shown that the transactivation
activity of HNF-4K is extinguished by deletion of the carboxy-
terminal end of its E-domain but is recovered by deletion of
the full-length E-domain in the context of a chimera GAL4-
HNF-4K on a promoter having a GAL4 binding site [6]. Our
results with R154X extend this ¢nding by indicating that
HNF-4K lacking the full-length E-domain can have a moder-
ate transactivation activity on the natural apoCIII and HNF-
1K promoters.
The ability of the R154X to transactivate the HNF-1K pro-
moter was cell-type speci¢c: this promoter was activated in
the kidney cell lines COS-1 and HEK 293T but not in the L-
cell line HIT-T15. Synergies between HNF-4K and other tran-
scription factors have been documented [28^30] and the cell-
type di¡erences observed on the HNF-1K promoter may re-
£ect di¡erences in the expression of cell-speci¢c transcription
factors.
The complete loss of transactivation of the HNF-1K pro-
moter by R154X in HIT-T15 cells is probably of physiological
importance since HNF-1K expression is required for normal
pancreatic L-cell function and mutations in the HNF-1K gene
are associated with another form of MODY, MODY3 [31]. In
HIT-T15 cells, none of the four promoters tested was trans-
activated by R154X, indicating a more severe impairment of
transactivation activity of this mutated protein in L-cells than
in non-L-cells. In addition, the R154X mutant may also exert
a dominant-negative e¡ect on the activity of wild-type HNF-
4K in L-cells. Thus, both loss-of-function and dominant-neg-
ative behaviour of R154X could a¡ect L-cell function thereby
leading to the L-cell dysfunction observed in MODY1 pa-
tients. The other nonsense HNF-4K mutant Q268X does not
exhibit a dominant negative activity in non-L-cells [2,15] and
determination of such a behaviour in L-cells will be of interest.
The functional properties of R154X likely account for the
clinical severity of diabetes observed in patients harbouring
this mutation [19].
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